|
News
CENTENNIAL, Colo., January 24, 2012—Cell>Point
announced today that it has entered into a
long-term collaboration agreement including
product licenses for Brazil with MJM Productos
Farmaceuticos e de Radioprotecao Ltda., or
“Radiopharmacus.”
The agreement leads with Cell>Point’s cancer and
cardiology molecular imaging agent—EC-G or,
specifically, 99mTc-EC-G
(99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine)—but
covers the entire portfolio of products being
developed by Cell>Point. EC-G has completed a
U.S. Phase 2 clinical trial for non-small cell
lung cancer diagnosis and staging, and a Phase 1
trial for coronary artery disease diagnosis.
In addition to the exclusive right to
manufacture and sell Cell>Point products in
Brazil following regulatory approval,
Radiopharmacus will also provide a range of
services including commercial scale synthesis,
cGMP (certified Good Manufacturing Practice)
manufacturing, preclinical studies, clinical
studies, and regulatory interface.
“We are very pleased to have a strategic partner
in Brazil like Radiopharmacus,” said Greg Colip,
Cell>Point chief executive officer.
“The broad scope of the relationship shouldhelp
shorten the lead time to complete the chemistry,
manufacturing and control process for each of
our products, and allow us to explore the
clinical feasibility of each product before
ramping up clinical-development investment.”
Regarded as one of the most promising and
attractive pharmaceutical markets in the
Americas, the Brazilian market is the 11th
largest globally at $17 billion dollars in
annual sales, per Business Monitor International
2010 data. The Brazilian pharmaceutical market
also has had consistently high growth over the
last decade.
Radiopharmacus will manufacture EC-G product
“kits” for Brazilian clinical studies and for
sale in Brazil, following marketing approval by
ANVISA, Brazil's National Health Surveillance
Agency.
Radiopharmacus is affiliated with a leading
Brazilian Contract Research Organization (CRO),
which will oversee clinical trials conducted in
Brazil.
CENTENNIAL, Colo.,
November 23, 2011—Cell>Point announced
today that the University of Texas M.D. Anderson
Cancer Center will present pre-clinical results
on Cell>Point’s therapeutic, Platinum-EC-G, for
Aggressive type-B Lymphoma at the 53rd American
Society of Hematology Annual Meeting December
10-13, 2011
CENTENNIAL, Colo.,
June 6, 2011—Cell>Point announced today that it
will present Phase 2 clinical trial results for
its cancer molecular imaging agent, 99mTc-EC-G
CENTENNIAL, Colo., March 18, 2010—Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.
Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.
Cell>Point adds Dr. Wayne Yakes to Board of Advisors - 11/22/2010.
CENTENNIAL, Colo., June 21, 2010—Cell>Point announced today that it has submitted to the US
Food and Drug Administration (FDA) an Investigational New Drug (IND) application for a Phase
1b/2 trial of its 99mTc‐EC‐G diagnostic in assessing patients with Coronary Artery Disease (CAD).
CENTENNIAL, Colo., June
3, 2010—Cell>Point announced today that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010.
CENTENNIAL,
Colo., February 10, 2010—Cell>Point
announced today that M. Donald Blaufox, M.D.,
Ph.D, will be coordinating principal
investigator for its Phase 2/3 clinical trial of
99mTc-EC-G for cancer diagnostic
imaging. The trial is currently underway.
Cell>Point receives
approval for Beta Cell Technology patent –
6/23/2009
CENTENNIAL, Colo., June
23, 2009 – Cell>Point today announced that the
U.S.P.T.O. approved its Beta Cell Technology
U.S. patent application (App. No. 10/942,615).
Cell>Point’s Beta Cell Technology is currently
in preclinical testing at The University of
Chicago Medical Center for imaging Type I
Diabetes.
Cell>Point adds Steven
Hanley to Board of Advisors – 6/18/2009
CENTENNIAL, Colo., June 18,
2009 – Cell>Point is pleased to announce that
Steve Hanely has joined our Board of Advisors.
Mr. Hanley is a former President of the Global
Imaging Division of Covidien . Mr. Hanley earned
his MBA and BS, Business Administration from
Marquette University.
Cell>Point retains the
Colorado Prevention Center to assist in
Cardiology Imaging Trial – 5/15/2009
CENTENNIAL, Colo., May 15,
2009 – Cell>Point today announced that the
Colorado Prevention Center has been retained to
assist the company in preparation of the Phase
II IND for the 99mTc-EC-G cardiology
imaging trial.
Cell>Point
adds Dr. Eric Kurzweil to Board of Advisors –
9/11/2008
CENTENNIAL, Colo.,
September 11, 2008 – Cell>Point is pleased to
announce that Eric Kurzweil, M.D., MBA has
joined our Board of Advisors. Dr. Kurzweil is
currently President of the Rocky Mountain Region
of Pediatrix. Pediatrix, a $2.63 billion market
cap company listed on the NYSE:PDX which
includes more than 900 physicians nationwide.
Dr. Kurzweil received his undergraduate degree
from Harvard University and his medical degree
from the University of Miami School of Medicine.
Dr. Kurzweil earned his master’s degree of
business administration from the University of
Colorado.
Cell>Point establishes
European subsidiary — 7|1|08
CENTENNIAL, Colo., July 1,
2008 - Cell>Point announced today that it has
established a subsidiary in the Netherlands,
Cell>Point Netherlands BV. Cell>Point plans to
expand its operation in Europe including
financial partners and European clinical trial
sites for its Phase III clinical trials in
99mTc-EC-G.
Cell>Point to present
at Wachovia 2008 Healthcare Conference — 1|25|08
CENTENNIAL, Colo., January
25, 2008 – Cell>Point, L.L.C. today announced
that it will present at the Wachovia 2008
Healthcare Conference, which will be held
January 29-31, 2008, at The Langham Hotel in
Boston, Mass. Cell>Point will present Thursday,
January 31 at 1:00 pm (Eastern Time) in the
Palmer Room.
Diagnostic Imaging April 2007 Article — 4|18|07
Cell>Point was featured in
the Diagnostic Imaging April 2007 issue "Small
biopharm company hatches plan to unseat FDG"
according to Terry Colip, Managing Partner of
Cell>Point. To view article go to
www.diagnosticimaging.com April 2007 issue.
Dr. F. David Rollo
joins Cell>Point as President — 9|12|06
CENTENNIAL, Colo.,
September 12, 2006 Terry Colip, Managing Partner
at Cell>Point today announced F. Dav ...
Cell>Point
expands clinical trial for Imaging Myocardial
Viability — 6|1|06
CENTENNIAL, Colo., June 1,
2006 -Cell>Point today announced it plans to
start a Phase II clinical trial to evaluate the
effectiveness of its 99mTc-EC-DG
(Technetium-99m-Ethylenedicys-teine-Deoxyglucose)
in diagnosing...
Cell>Point
named Biotech Rising Star of the Year — 11|8|05
ENGLEWOOD, Colorado - November,
8, 2005 - Cell>Point was named Biotech "Rising
Star of the Year" by the Colorado BioScience
Association according to Terry Colip, Managing
Partner of Cell>Point...
Cell>Point
acquires Oligosaccharide Conjugate License —
6|3|05
HOUSTON, Texas - June 3,
2005 - Cell>Point obtained the worldwide patent
and technology license to Oligosaccharide
Conjugates for Dual Imaging and
Radio/Chemotherapy developed at The University
of Texas M. D. Anderson Cancer Center. This
novel technology is facilitating the development
of combination modality diagnostic imaging
agents and new combination
radio/chemotherapeutic agents for use in
oncology, cardiology, neuroendocrinology and
infectious diseases...
Cell>Point
featured in Aunt Minnie — 5|20|05
ENGLEWOOD,Colorado-May20,2005-Cell>Point
was featured in the following Aunt Minnie
article
BiotechfirmCell>Point sees promise for oncology
SPECT- By: Kate Madden Yee ...
EC Technology
featured in Basel, Switzerland — 4|21|05
HOUSTON, Texas - April 21, 2005 -
Cell>Point announced today that David J. Yang,
Ph.D. will present our EC Technology at the
Joint Meeting of the Austrian, German, and Swiss
Societies of Nuclear Medicine to be held in
Basel, Switzerland (April 27-30, 2005) ...
Cell>Point to present at 30th Annual Deutsche Bank
Health Care Conference — 4|20|05
ENGLEWOOD, Colorado - April 20, 2005
-Cell>Point will be a presenting company at the
30th Annual Deutsche Bank Health Care Conference
to be held in Baltimore, May 2-4, 2005. The
webcast can be viewed at
http://www.corporate-ir.net/ireye/confRegistration.zhtml?ticker=W189917&item_id=ew,1055963,1,189917,438136,524157
...
Cell>Point acquires N4 Technology License —3|1|05
HOUSTON, Texas - March 1, 2005 -
Cell>Point obtained the worldwide patent and
technology license on February 14, 2005 to
tatraazacyclopentadecane (N4)
technology developed at The University of Texas
M.D. Anderson Cancer Center. N4
Technology will form the foundation for the
development of Positron Emission Tomography
imaging agents using generator based isotopes as
well as compounds for imaging and treating
neuroendocrine tumors and certain diseases
affecting the centra ...
Cell>Point to Present at Rice Forum —
2|22|05
HOUSTON, Texas - February 22, 2005 -
Cell>Point has been selected to be a presenting
company at the 4th Annual Rice Alliance Life
Science Technology Venture Forum on March 11,
2005 at Rice University. Greg R. Colip,
President of the company, will present an
overview of the company and its technology
platforms. The Rice Alliance Forum brings
together biotechnology companies, angel
investors, venture capital firms and law firms
who specialize in the area of biotechnology. The
Forum ...
Dr. Saad Zakko joins Scientific Advisory Board —
9|8|04
HOUSTON, Texas - September 1, 2004
?Cell>Point is pleased to announce that Dr. Saad
Zakko has joined our Scientific Advisory Board.
Dr. Zakko has been Consultant to the Department
of Nuclear Medicine at Dubai Hospital
Cell>Point completes clinical pilot study on 99mTc-EC-Annexin
V — 4|1|04
HOUSTON,Texas-April1,2004 -Cell>Point
L.L.C. completes clinical pilot study on
99mTc-EC-Annexin V at The University of
Texas M.D. Anderson Cancer Center. The study
evaluated the use of 99m
Tc-EC-Annexin V to assess tumor apoptosis
(programmed cell death) in patients with primary
breast cancer and to detect an ...
Royal Philips Electronics collaborates with Cell>Point
— 9|29|03
HOUSTON, Texas - September 29, 2003 -
Royal Philips Electronics (NYSE: PHG, AEX: PHI)
announced today that it will collaborate with
Cell>Point, L.L.C, a biotechnology company based
in Englewood, Colo., to optimize Cell>Point's
novel diagnostic imaging agent on Philips'
SKYLight Ò gantry-free gamma camera. The
companies will share clinical trial costs to
develop the best imaging techniques for improved
clinical information and accuracy of diagnoses.
The joint goal is to develop ...
Cell>Point L.L.C. Completes Exclusive License
Negotiations for Second Technology Platform In Situ Hydrogel — 7|1|03
In July 2003, the company completed
exclusive license negotiations with M.D.
Anderson for a second technology platform, In
Situ Hydrogel, which will be used for local
regional chemotherapy and radiotherapy. In
comparison with other hydrogel technologies, In
Situ Hydrogel is the only hydrogel formulation
capable of delivering a high yield load of a
therapeutic radionuclide like 188Re
directly to the tumor site without leakage into
surrounding tissue. The In Situ Hydrog ...
Cell>Point L.L.C. Preparing to Conduct Studies —
10|1|02
HOUSTON, Texas - October 2002 - Cell>Point
L.L.C. is preparing to commence clinical
biokinetic and biodistribution studies at The
University of Texas M.D. Anderson Cancer Center
on 99mTc-EC-Metronidazole, 99mTc-EC-Annexin
V and 99mTc-EC-Cox-2. If results from
the studies are as expected, Cell>Point will
prepare and submit IND applications with the FDA
for the three "kit" compounds...
Cell>Point Receives Approval of its Investigations New
Drug Application for 99mTc-EC-Deoxyglucose — 6|1|02
HOUSTON, Texas - June 2002 - Cell>Point
L.L.C. (Englewood, CO) received approval of its
Investigational New Drug Application for
99mTc-EC-Deoxyglucose (known in the
clinical trial as "CP6262") from the FDA on June
26. The Phase I clinical trial will be conducted
at The University of Texas M.D. Anderson Cancer
Center in Houston, Texas. CP6262 is a
technetium-99m labeled molecular
imaging agent that will be used as a diagnostic
tool in oncology to identify active tumor ...
Cell>Point, L.L.C. Executes Exclusive Worldwide Patent
and Technology License Agreement for ethylenedicysteine — 7|1|01
HOUSTON, Texas - July 2001 - Cell>Point,
L.L.C. executed an exclusive worldwide Patent
and Technology License Agreement with The
University of Texas M.D. Anderson Cancer Center
for ethylenedicysteine ("EC") drug conjugate
technology which functions as a chemical bridge
linking diagnostic radio-tracers or therapeutic
radionuclides to ligand disease target seekers
or novel FDA approved drugs...
|
